Literature DB >> 6831430

Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.

E S Kleinerman, K L Erickson, A J Schroit, W E Fogler, I J Fidler.   

Abstract

Peripheral blood monocytes were isolated from normal human donors by separation on a continuous Percoll gradient and adherence to yield preparations of blood monocytes with a high degree of purity (greater than 99%). The monocytes were incubated in vitro with medium alone or with multilamellar liposomes that contained either a lipophilic derivative of muramyl dipeptide, muramyl tripeptide (MTP-PE), or medium. The cytotoxic properties of the monocytes were assessed by an in vitro radioisotope release assay against various allogeneic targets. Monocytes that have phagocytosed liposomes containing MTP-PE were rendered tumoricidal. These monocytes lysed cells of three different tumorigenic lines but not cells of two nontumorigenic lines. The ability of MTP-PE-activated human blood monocytes to recognize and selectively lyse neoplastic cells was also demonstrated under cocultivation conditions. We conclude that human blood monocytes can be rendered tumoricidal after interaction with liposomes containing MTP-PE.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831430

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.

Authors:  Gangxiong Huang; Ling Yu; Laurence Jn Cooper; Mario Hollomon; Helen Huls; Eugenie S Kleinerman
Journal:  Cancer Res       Date:  2011-11-10       Impact factor: 12.701

2.  Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.

Authors:  P M Anderson; P Meyers; E Kleinerman; K Venkatakrishnan; D P Hughes; C Herzog; W Huh; R Sutphin; Y M Vyas; V Shen; A Warwick; N Yeager; C Oliva; B Wang; Y Liu; A Chou
Journal:  Pediatr Blood Cancer       Date:  2013-08-31       Impact factor: 3.167

Review 3.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

4.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

5.  Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.

Authors:  A F Brownbill; D G Braun; P Dukor; G Schumann
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.

Authors:  T Asano; K Matsushima; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

7.  Toward a drug development path that targets metastatic progression in osteosarcoma.

Authors:  Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

Review 8.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

9.  Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.

Authors:  M Maeda; T Asano; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

10.  A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.

Authors:  S Sone; T Utsugi; P Tandon; M Ogawara
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.